: During this window, Novacyt was in the process of selling non-core assets, such as its NOVAprep unit and clinical laboratory business, to focus on molecular testing.
: In May 2019, the company’s molecular division, Primerdesign , launched the genesig® q32 qPCR instrument. This next-generation tool was a critical "update" to their hardware lineup, designed to provide faster PCR cycle times. novacyy 20190526 sd upd
: Documentation regarding the hand-over or operational changes during the divestment of their clinical lab units. : During this window, Novacyt was in the
: Interestingly, Novacyt later acquired Southern Cross Diagnostics (SCD). While that acquisition occurred more recently (early 2026), the initials "SD" frequently appear in their internal supply chain and distribution documentation. The Evolution of Novacyt Post-2019 : During this window